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OBJECTIVES: To assess the economic impact of using drug-eluting stents(DES) 
versus bare-metal stents(BMS) in patients with ST-elevation acute myocardial 
infarction(STEMI) in Korea from a societal perspective METHODS: A cost-minimi-
zation analysis using a decision analysis model comparing DES and BMS was per-
formed since the mortality was comparable between two stents in a random-effects 
meta-analysis from a systematic review of fourteen randomized controlled trials(RCTs) 
with 7,654 patients. One-year time period was used since most of STEMI patients 
require an emergency procedure and revascularization occurs within one year. The 
probabilities of revascularization for each stent were derived from the meta-analysis 
and the rest of probabilities and costs were obtained from the national reimbursement 
database of Health Insurance Review and Assessment(HIRA) between 2006–2009. To 
identify stent-naïve STEMI patients deﬁned as having no stenting during one-year of 
washout period, we used two-years of intake period with diagnosis code I21 and ER 
visit. We also used a micro-costing method based on six experts’ opinion. Uncertainty 
was evaluated using tornado diagrams and probabilistic sensitivity analyses. 
RESULTS: Incidence of revascularization after initial stenting was 5.42% and 11.79% 
for DES and BMS, respectively. The transition probabilities of DES-to-DES, DES-to-
BMS, DES-to-CABG, DES-to-balloon were 62.8%, 1.5%, 4.1%, and 31.7%. The 
transition probabilities of BMS-to-DES, BMS-to-BMS, BMS-to-CABG, BMS-to-bal-
loon were 52.8%, 7.6%, 0.0%, and 39.5%. The average costs of DES and BMS from 
HIRA data in 2009 value were US$11,007/person·year and US$9,771/person·year, 
respectively. Those from a micro-costing method were US$4966/person·year for DES 
and US$4730/person·year for BMS. DES versus BMS resulted in higher costs for 
US$1237/person·year using HIRA data and US$236/person·year using micro-costing 
approach. The model was highly sensitive to the probability and costs of having no 
revascularization. CONCLUSIONS: The use of BMS versus DES in STEMI patients 
may be a cost-saving procedure. Local large RCTs are needed to minimize the uncer-
tainty of results.
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OBJECTIVES: Open-heart surgery requires cardiopulmonary bypass (CPB) along with 
transfusions to maintain adequate blood volume. The purpose of this study was to 
identify the economic impact of using an artiﬁcial oxygen carrier instead of blood 
transfusion in cardiac surgery with CPB at the Mexican Institute of Social Security 
(know in Mexico as IMSS) from the health care payer’s perspective. METHODS: A 
cost-minimization analysis was developed in a randomized clinical trial. Seven patient 
candidates for cardiac valve replacement received 5 ml/kg of preﬂuorocarbon (PFC) 
artiﬁcial oxygen carrier during cardiac surgery. They were compared with 11 patients, 
which received conventional blood transfusions. Clinical, biochemical and hemody-
namic parameters, and survival were measured for both groups during hospitalization. 
Resources and materials used and cost data were obtained from the patients’ hospital 
records for the hospitalization period. RESULTS: Clinical, biochemical and hemody-
namic parameters did not show any signiﬁcant differences between groups. All patients 
were discharged noting clinical improvement. The hospital stay of the conventional 
blood transfusion group was 5.55 ± 3.62 days vs. 5.0 ± 0.82 days in the PFC group. 
The mean per patient cost of blood products in the conventional blood transfusion 
group was US $993.40, and the PFC group mean per patient cost was US $469.48. 
The total mean per patient cost during hospitalization in the conventional blood 
transfusion group was US $31,261.87 ± US $16,239.60. The PFC’s total mean per 
patient cost was US $27,358.90 US ± US $9,671.00 (p = 0.57). The difference in cost 
was US $3902.97 per patient. CONCLUSIONS: The use of PFC has similar clinical 
outcomes as the use of conventional blood transfusion in cardiac surgery with CPB, 
and it could present potential savings.
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ECONOMIC ANALYSIS OF ENDOVASCULAR STENTING FOR 
PERIPHERAL ARTERIAL DISEASE IN LONG LESIONS OF THE 
SUPERFICIAL FEMORAL ARTERY
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OBJECTIVES: To evaluate the cost-effectiveness of endovascular stent treatments used 
in the revascularization of long lesions of the superﬁcial femoral artery (SFA) for 
patients with peripheral arterial disease (PAD). METHODS: A three-state Markov 
model was constructed and analyzed from the societal perspective. A cycle length of 
six months was used to reﬂect the average number of days between reinterventions 
and the model was simulated over a lifetime time horizon with a discount rate of 3%. 
Mean health care costs were calculated for the initial procedure, follow-up, reinterven-
tions, adverse events, and surveillance. Procedural costs were derived from the 2009 
Medicare data and device costs were obtained from the March 2009 Intercontinental 
Marketing Services (IMS) data. The main measure of effectiveness was quality adjusted 
life expectancy expressed in quality adjusted life years (QALYs). Quality of life esti-
mates were based on utilities that were derived from the literature and a multicenter, 
randomized, prospective study that compared the use of bare to covered nitinol stents 
in patients with lower limb PAD. RESULTS: For the average patient, a 66 year old 
male, revascularization with a covered nitinol stent decreased the number of reinter-
ventions needed and thus, decreased lifetime expenditures compared to bare nitinol 
stents. The undiscounted and discounted incremental cost-effectiveness ratios (ICERs) 
calculated for the base case scenario was $63,675/QALY and $80,564/QALY, respec-
tively. A one-way sensitivity analysis over the parameters for cost, adverse events, 
utilities, cycle length, age, and discount rate, demonstrated that covered nitinol stent-
ing would be the preferred treatment over bare nitinol stenting except in the case at 
age 90 and in the case where reintervention costs for bare nitinol stenting was reduced 
by 25%. CONCLUSIONS: Covered nitinol stenting for the revascularization of long 
lesions in the SFA is a cost-effective treatment strategy compared to bare nitinol 
stenting.
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OBJECTIVES: This study assessed the long-term cost-effectiveness of rosuvastatin 
10 mg therapy in reducing the incidence of major cardiovascular disease (CVD) events 
and mortality in patients at higher risk of CVD events (Framingham risk ≥10%). 
METHODS: A probabilistic Monte Carlo simulation model estimated long-term cost-
effectiveness of rosuvastatin therapy (10 mg daily) for the prevention of CVD mortal-
ity and morbidity in patients with Framingham 10-year CVD risk >10%. The model 
was developed based on the JUPITER (Justiﬁcation for the Use of statins in Primary 
prevention: an Intervention Trial evaluating Rosuvastatin) trial ﬁndings and includes 
modeling of initial and subsequent CVD events and death over time. Using rosuvas-
tatin 20 mg efﬁcacy ﬁndings from the JUPITER trial, efﬁcacy of rosuvastatin 10 mg 
was estimated using the Framingham equation based on effects on total cholesterol/
high-density lipoprotein cholesterol ratio. The quarterly event probabilities were used 
to construct survival curves for patients in both the treatment and placebo groups, 
and the relative risk of rosuvastatin was estimated and extrapolated beyond the trial 
duration. A payer perspective was used with direct medical costs, and 10-year, 20-year 
and lifetime horizon. RESULTS: For a hypothetical cohort of 100,000 patients (age 
65 years, 60% men) at moderate or high risk of CVD events (Framingham risk ≥10%), 
estimated quality-adjusted life-years (QALYs) gained with rosuvastatin therapy, com-
pared with placebo, was 31,079 over a lifetime horizon, and 22,598 and 8,580 over 
20- and 10-year horizons, respectively. Rosuvastatin 10 mg treatment avoided 
approximately 11,044 events over the lifetime (5,665 non-fatal MIs, 2,741 non-fatal 
strokes, and 3,448 CVD deaths avoided). Estimated incremental cost-effectiveness 
ratio (ICER) for cost per QALY was $7,974 (lifetime), $12,865 (20-year horizon), 
and $53,101 (10-year horizon). CONCLUSIONS: Study results indicate rosuvastatin 
10 mg treatment to be a cost-effective treatment alternative in patients at a higher risk 
of CVD events.
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OBJECTIVES: To estimate the clinical and economic costs and effects of 2 year treat-
ment with high intensity atorvastatin therapy (80 mg) versus moderate to high dose 
simvastatin and pravastatin therapies in Spanish patients with acute coronary syn-
drome (ACS). METHODS: Using data from statin trials in ACS (MIRACL, PROVE-
IT, AtoZ) and priors from published statin meta analyses (CTT, Law), efﬁcacy is 
estimated based on a Bayesian meta-analysis linking reductions in LDL cholesterol to 
reductions in secondary cardiovascular (CV) events (MIs, strokes, CV deaths). A 
Markov model combines estimates of the occurrence of later events; Spanish cost data; 
and quality of life. Risks are taken from the ACS CURE study. A baseline event risk 
of 12.1% is used in the ﬁrst 6 months and 3.89% during later months. The time 
horizon of the analyses is lifetime (50 years). RESULTS: Compared to simvastatin 
80 mg, the cost per QALY for atorvastatin 80 mg treatment for 2 years is very 
cost effective at 314,123. Accounting for a 50% price reduction post LOE will result 
in atorvastatin being even more cost effective. When compared to treatment with 
pravastatin 40 mg, the cost per QALY is 34,958 for atorvastatin 80 mg, which 
becomes dominant when the price reduction is included. ICERs improve when risk 
with age is reduced, lower discount rates are used, and when atorvastatin cost is 
decreased. CONCLUSIONS: Preliminary ﬁndings show that using atorvastatin 80 mg 
to treat high risk Spanish ACS patients is a very cost-effective intervention, with cost 
effectiveness ratios of <315,000 versus simvastatin 80 mg and <35,000 versus pravas-
tatin 40 mg. Moreover, following LOE, the cost per QALY becomes extremely cost 
